Abstract
Resveratrol is a plant-derived compound possessing antioxidant, antiinflammatory, and antitoxicant properties, which is used as a biologically active additive (dietary supplement) for the prevention of myocardial infarction, diabetes mellitus type 1 and 2, and cancer disorders. The aim of this study was the development and pharmacokinetic study of a nanoparticulate formulation of resveratrol. The proposed lab-scale method ensures the preparation of particles with sizes on a submicron scale at a resveratrol yield of 70 - 100% and a resveratrol content of 15 - 20%. Peroral administration of the initial resveratrol resulted in low absorption (19%), while the nanoparticulate formulations increased the bioavailability of resveratrol up to 39 and 61% for Eudragit RL- and lecithin/chitosan-based nanoparticles, respectively. Four- to five-fold increase in the peak concentration of nanoparticulate resveratrol in the plasma has also been observed in comparison to the initial drug. Thus, the conversion of resveratrol into nanoparticle-based forms for peroral administration increases drug solubilisation and subsequent effective absorption in the bloodstream.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
